Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial Article

cited authors

  • Mitra, Anirban P.; Narayan, Vikram M.; Mokkapati, Sharada; Miest, Tanner; Boorjian, Stephen A.; Alemozaffar, Mehrdad; Konety, Badrinath R.; Shore, Neal D.; Gomella, Leonard G.; Kamat, Ashish M.; Bivalacqua, Trinity J.; Montgomery, Jeffrey S.; Lerner, Seth P.; Busby, J. Erik; Poch, Michael; Crispen, Paul L.; Steinberg, Gary D.; Schuckman, Anne K.; Downs, Tracy M.; Svatek, Robert S.; Mashni, Joseph; Lane, Brian R.; Guzzo, Thomas J.; Bratslavsky, Gennady; Karsh, Lawrence, I; Woods, Michael E.; Brown, Gordon A.; Canter, Daniel; Luchey, Adam; Lotan, Yair; Krupski, Tracey; Inman, Brant A.; Williams, Michael B.; Cookson, Michael S.; Keegan, Kirk A.; Andriole, Gerald L.; Sankin, Alexander, I; Boyd, Alan; O'Donnell, Michael A.; Philipson, Richard; Yla-Herttuala, Seppo; Sawutz, David; Parker, Nigel R.; McConkey, David J.; Dinney, Colin P. N.

authors

Publication Date

  • February 26, 2022

webpage

published in

category

keywords

  • Antiadenovirus antibody
  • Bladder cancer
  • Companion biomarker
  • Gene therapy
  • Treatment efficacy

start page

  • 223

end page

  • 228

volume

  • 81

issue

  • 3